2019 was another banner year for precision oncology with the approval of a number of drugs targeting novel genomic alterations, the availability of a third pan-cancer indication, and the commercial launch of new biomarker tests for predicting drug response, such as homologous repair deficiency.
By Precision Oncology News’ count, in 2019, nearly 75 percent of the 27 personalized drugs the US Food and Drug Administration approved were for precision oncology indications. Five were new molecular entities and 15 were expanded indications of previously approved drugs.
To read the full article, click here.